Tag Archives: Accelerate Long Island

East Coast Biotech Roundup: Regeneron, Synergy, Foundation & More

Biotech was in recovery mode this week. After Biogen’s (NASDAQ: BIIB) disappointing quarterly results send the sector’s indices downward, investors looked to other industry stalwarts, like Gilead Sciences (NASDAQ: GILD), to right the ship (Gilead succeeded, as Alex Lash writes here). On the East Coast, a couple of New York biotechs helped the cause. Those […]

Accelerate LI, Eyeing New Seed Fund, Debuts Ninth Grad: Envisagenics

It’ll be several years before we’ll know whether the efforts of Accelerate Long Island lead to successful, sustainable companies. But with the emergence of its latest graduate today, Envisagenics, Accelerate LI can now say it’s helped get nine startups hailing from Long Island’s research institutions off the ground. Accelerate LI and its strategic partner, the […]

Posted in National blog main, New York, New York blog main, New York top stories | Tagged Accelerate Long Island, Adrian Krainer, Aranata Pharmaceuticals, Cold Spring Harbor Laboratory, Columbia University, deals, Empire State Development, Envisagenics, Goddard Labs, Green Sulfcrete, James Watson, Jove Equity Partners, Launchpad Huntington, Life Sciences, Long Island Emerging Technologies Fund, Maria Luisa Pineda, Martin Akerman, Michael Schatz, Michael Zhang, New York Genome Center, New York State Innovation Venture Capital Fund, PolyNova, Right Dose, RNA, Stacey Sikes, startups, Stony Brook University, Symbiotic Health, SynchroPET, Topspin Fund, Traverse Biosciences, University of Texas, VC, Yaniv Erlich | Comments Off

East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More

New startups. New data. Financings. Acquisitions. Legal tussles. FDA advisory panels. It’s been that kind of week in East Coast biotech. So grab some coffee and let’s roll through this week’s headlines. —This week a new type of cholesterol-lowering drug was in the spotlight, a class of injectable therapies that block the protein known as […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged Accelerate Long Island, Acute Myeloid Leukemia, Agios Pharmaceuticals, Alan Crane, alirocumab, Alnylam Pharmaceuticals, Amgen, Amicus Therapeutics, Ankit Mahadevia, Antibiotics, Beta-Thalassemia, Biotech, BlueBird Bio, Celgene, Chuck Wilson, Clarus Ventures, Codagenix, deals, Dicerna Pharmaceuticals, evolocumab, FDA, Gary Glick, Gene Therapy, Immunotherapy, Inflammatory Bowel Disease, IPO, Ironwood Pharmaceuticals, J. Robert Coleman, Life Sciences, Lundbeckfond Ventures, Lycera, Merck, Merck Research Ventures, New Enterprise Associates, PCSK9, Polaris Partners, post-partum depression, Praluent, pyruvate kinase deficiency, Regeneron Pharmaceuticals, Repatha, RNA Interference, Roundups, Sage Therapeutics, Sanofi, Scott Requadt, Seattle Genetics, Sirna Therapeutics, Spero Therapeutics, startups, Stroma, the Kraft Group, Topspin Partners, Unum Therapeutics, Vaccine, Xtuit Pharmaceuticals | Comments Off

With $2M, Codagenix Becomes Accelerate LI’s First VC-Backed Grad

Accelerate Long Island’s main mission has been to turn the science at its nearby research institutions into full-fledged companies with venture investors of their own. With a small funding round being announced today, Codagenix has become the first one of those projects that can make that claim. Codagenix has raised a $2 million Series A […]

Posted in Boston blog main, National blog main, New York, New York blog main, New York top stories | Tagged Accelerate Long Island, Affinity, Astellas Pharma, Broad Hollow Bioscience Park, Codagenix, Cold Spring Harbor Laboratory, deals, Farmingdale State College, Genocea Biosciences, Goddard Labs, Green Sulfcrete, J. Robert Coleman, Jove Equity Partners, Life Sciences, NIH, OSI Pharmaceuticals, PolyNova, Right Dose, startups, Stony Brook University, SynchroPET, Topspin Fund, Topspin Partners, Traverse Biosciences, Vaccine, VC, virus, Visterra | Comments Off

Big Apple Biotech “Bootstraps” Forward at NewYorkBio Meeting

Tom Cirrito was dining out at a Mexican restaurant in midtown Manhattan over a decade ago when he overheard something that piqued his interest. At a table next to him, someone was talking about biotech. Cirrito, then an analyst at Piper Jaffray, was intrigued. He butted in, and his life changed. His restaurant neighbor was […]

Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged Accelerate Long Island, Accelerator Corp., Allovate, Codagenix, David Schubert, Diagnostics, entrepreneurs, Entrepreneurship Lab NYC, EpiBone, Eric Gertler, Erick Berglund, Gene Therapy, Genomic Expression, Gitte Pedersen, Harlem Biospace, Hina Chaudhry, Icahn School of Medicine at Mount Sinai, Ivan Bergstein, J. Robert Coleman, Kate Rochlin, Life Sciences, Long Island Emerging Technologies Fund, New York City Economic Development Corp., New York Genome Center, NewYorkBio, Novozymes, startups, Stemline Therapeutics, Stony Brook University, Tom Cirrito, vaccines, VentriNova, Weill Cornell Medical College | 1 Comment

Accelerate LI’s Latest Startup Aims to Rewire Viruses With Software

Accelerate Long Island seeded its first batch of startups earlier this year, and today it has circled back with its latest investment—a company purporting to use computer tools to whip up synthetic viruses and create new vaccines. Accelerate LI and its strategic funding partner, the Long Island Emerging Technologies Fund, have invested $100,000 total—$50,000 apiece—in […]

Posted in Boston blog main, National blog main, New York, New York blog main, New York top stories | Tagged Accelerate Long Island, Affinivax, Codagenix, dengue virus, E. coli, Eckard Wimmer, Genocea Biosciences, influenza, Jove Equity Partners, Life Sciences, Long Island Emerging Technologies Fund, Long Island High Technology Incubator, National Institutes of Health, respiratory syncytial virus, Robert Coleman, startups, Steffen Mueller, Stony Brook University, Topspin Partners, vaccines, Visterra | Comments Off

East Coast Biotech Roundup: Accelerate LI, ASCO, Akebia, & More

Fresh off Memorial Day barbecues, the life sciences world descended on Chicago last week for the American Society of Clinical Oncology’s annual meeting. But it was quickly back to the grind afterward, with deals, IPO news, and much more filling up the headlines on the East Coast. —After a few years fine-tuning its investment strategy, […]

Posted in Boston, Boston blog main, National blog main, New York blog main | Tagged Accelerate Long Island, Akebia Therapeutics, Alexandria Venture Investments, American Society of Clinical Oncology, Anemia, ASCO, AstraZeneca, Biogen Idec, Brad Loncar, Bristol-myers Squibb, cancer, cleantech, Clostridium difficile, Cystic Fibrosis, David Berry, deals, Drugs, Enso Ventures, entinostat, Flagship Ventures, Francois Nader, Goddard Labs, Green Sulfcrete, hemophilia A, hemophilia B, Hepatitis C, Idenix Pharmaceuticals, IPO, Ivacaftor, John Butler, Life Sciences, Long Island Emerging Technologies Fund, Mark Lesko, Mayo Clinic, Merck, Microbiome, NPS Pharmaceuticals, obesity, Pfizer, PolyNova, Radius Health, Roche/Genentech, Roger Pomerantz, Seres Health, SynchroPET, Syndax Pharmaceuticals, Tech, Traverse Biosciences, VC, Vertex Pharmaceuticals, Zafgen | Comments Off

Tag Archives: Accelerate Long Island

Archives

Meta